| Name | Title | Contact Details |
|---|
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Jamol Laboratories is a Emerson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Jamieson Wellness is a Canadian company that manufactures, distributes, and markets high quality natural health products. Their portfolio includes the Jamieson brand, which is Canadas #1 consumer health brand, as well as the youtheory, Progressive, Sm...
Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.